SWOG clinical trial number
S0120
A Prospective Observational Biologic Study of Asymptomatic Patients With Monoclonal Gammopathy and Plasma Proliferative Disorders
Abbreviated Title
Observational MGUS / Asymptomatic Myeloma and Plasma Proliferative Disorders
Pts with ANY plasmaproliferative diseases not requiring therapy (including MGUS, asymptomatic myeloma, IgM MGUS/smoldering plasma cell dyscrasias and solitary plasmacytoma) are eligible. Necessary baseline studies to determine eligibility, except bone marrow, must be obtained within 28 days prior to registration. X-rays and scans must be completed within 6 months prior to registration. Pts must be willing to submit research bone marrow aspirate specimens for gene expression analysis, and immunologic assessment. Pts must be willing to submit blood samples for immunologic assessment as outlined in the protocol. Pts must not have received prior treatment. Concurrent or prior use of bisphosphonates is permitted. Zubrod PS 0-2. Submission of local cytogenetics report and FISH analysis report is strongly suggested. No prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which pt has been disease-free for 2 years.
2018
Antigen-mediated regulation in monoclonal gammopathies and myeloma
S Nair;J Sng;C Boddupalli;A Seckinger;M Chesi;M Fulciniti;L Zhang;N Rauniyar;M Lopez;N Neparidze;T Parker;NC Munshi;R Sexton;B Barlogie;R Orlowski;L Bergsagel;D Hose;RA Flavell;PK Mistry;E Meffre;M Dhodapkar JCI Insight Apr 19;3(8)
PMid: PMID29669929 | PMC number: PMC5931125
2011
SWOG S0120 observational trial for MGUS and asymptomatic multiple myeloma (AMM): imaging predictors of progression for patients treated at UAMS
C Heuck;R Sexton;M Dhodapkar;Q Zhang;S Usmani;B Nair;F van Rhee;A Hoering;J Crowley;J Shaughnessy;R Orlowski;B Barlogie Blood 118(21):abst 3955; American Society of Hematolgy, poster presentation
2009
Role of T-cell immunity to embryonal stem (ES) cell antigen SOX2 in the progression of myeloma
MV Dhodapkar;V Bolejack;J Shaughnessy;P Matthews;R Pickering;P Qu;A Hoering;J Crowley;B Barlogie Journal of Clinical Oncology 27:15s, abst.#8522
2007
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis [PMID17023574; PMC1794073]
F Zhan;B Barlogie;V Arzoumanian;Y Huang;DR Williams;K Hollmig;M Pineda-Roman;G Tricot;F van Rhee;M Zangari;M Dhodapkar;JD Shaughnessy, Jr Blood 109(4):1692-1700
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy [PMID17389240; PMC2118551]
R Spisek;A Kukreja;LC Chen;P Matthews;A Mazumder;D Vesole;S Jagannath;HA Zebroski;AJG Simpson;G Ritter;B Durie;J Crowley;JD Shaughnessy Jr;MJ Scanlan;AO Gure;B Barlogie;MV Dhodapkar Journal of Experimental Medicine 204(4):831-840
2005
Gene expression profiling of bulk CD138+ plasma cells in preneoplastic gammopathy/asymptomatic myeloma identifies distinct subsets of patients
MV Dhodapkar;F Zhan;E Rasmussen;B Burington;B Durie;J Crowley;B Barlogie;J Shaughnessy Blood (ASH Annual Meeting Abstracts) 106(11): #1218
Differential antigenic targets of anti-tumor immune response and selective immunity to stem cell associated group B SOX proteins in preneoplastic versus malignant gammopathy
R Spisek;L Chen;M Scanlan;A Simpson;G Ritter;E Rasmussen;J McCoy;A Murray;J Krasovsky;B Durie;J Crowley;A Mazumder;S Jagannath;B Barlogie;A Gure;M Dhodapkar Blood (ASH Annual Meeting Abstracts) 106(11): #5116
